Kenvue Inc. (KVUE) is a publicly traded Consumer Defensive sector company. As of October 3, 2026, KVUE trades at $17.20 with a market cap of $33.08B and a P/E ratio of 19.59. KVUE moved -0.23% today. Year to date, KVUE is -0.69%; over the trailing twelve months it is +9.35%. Its 52-week range spans $14.02 to $25.17. Analyst consensus is neutral with an average price target of $19.25. Rallies surfaces KVUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kenvue says post-hoc analysis links earlier 5% minoxidil use to higher hair regrowth in men: Kenvue said a post-hoc Phase III analysis linked earlier use of 5% minoxidil foam with stronger hair regrowth outcomes in men with androgenetic alopecia. The findings are slated for presentation at the EADV Congress in Vienna from Sept. 30 to Oct. 3, 2026.
| Metric | Value |
|---|---|
| Price | $17.20 |
| Market Cap | $33.08B |
| P/E Ratio | 19.59 |
| EPS | $0.88 |
| Dividend Yield | 0.21% |
| 52-Week High | $25.17 |
| 52-Week Low | $14.02 |
| Volume | 11.53M |
| Avg Volume | 0 |
| Revenue (TTM) | $15.41B |
| Net Income | $1.66B |
| Gross Margin | 58.19% |
7 analysts cover KVUE: 0 strong buy, 1 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $19.25.